Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leader in innovation, dedicated to developing first‑in‑class antibody therapies that target novel tumor antigens utilizing its proprietary, proteomics target discovery platform, OGAP-Verify. Founded in 2004, OBT has become a pioneer in precision oncology through cutting‑edge research and global strategic collaborations with leading biopharmaceutical companies, including Roche, GSK, Zymeworks and Boehringer Ingelheim. Also, company’s robust pipeline of ADCs and other antibody‑based therapies underscores its commitment to delivering breakthrough treatments to patients worldwide.